Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 17, 2015, Pages 6733-6746

  Estrada, Anthony A ^a   Sweeney, Zachary K ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; INDOLE DERIVATIVE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; ANTIPARKINSON AGENT; GUANOSINE TRIPHOSPHATE; LRRK2 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

BRAIN; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; METABOLISM; MUTATION; PARKINSON DISEASE; PERMEABILITY; PROTEIN CONFORMATION;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; GUANOSINE TRIPHOSPHATE; HUMANS; MUTATION; PARKINSON DISEASE; PERMEABILITY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84941584887     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00261     Document Type: Review

References (110)

1. Jankovic, J. Parkinson's disease: clinical features and diagnosis J. Neurol. Neurosurg. Psychiatry 2008, 79, 368-376
2. Braak, H.; Ghebremedhin, E.; Rüb, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson's disease-related pathology Cell Tissue Res. 2004, 318, 121-134
3. Schapira, A. H. V. Neurobiology and treatment of Parkinson's disease Trends Pharmacol. Sci. 2009, 30, 41-47
4. Kamb, A.; Harper, S.; Stefansson, K. Human genetics as a foundation for innovative drug development Nat. Biotechnol. 2013, 31, 975-978
5. Kauselmann, G.; Dopazo, A.; Link, W. Identification of disease-relevant genes for molecularly-targeted drug discovery Curr. Cancer Drug Targets 2012, 12, 1-13
6. Lin, M. K.; Farrer, M. J. Genetics and genomics of Parkinson's disease Genome Med. 2014, 6, 48
7. Martin, I.; Dawson, V. L. V.; Dawson, T. T. M. Recent advances in the genetics of Parkinson's disease Annu. Rev. Genomics Hum. Genet. 2011, 12, 301-325
8. Nuytemans, K.; Theuns, J.; Cruts, M.; Van Broeckhoven, C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update Hum. Mutat. 2010, 31, 763-780
9. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R. J.; Calne, D. B.; Stoessl, A. J.; Pfeiffer, R. F.; Patenge, N.; Carbajal, I. C.; Vieregge, P.; Asmus, F.; Muller-Myhsok, B.; Dickson, D. W.; Meitinger, T.; Strom, T. M.; Wszolek, Z. K.; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 2004, 44, 601-607
10. Paisan-Ruiz, C.; Jain, S.; Evans, E. W.; Gilks, W. P.; Simon, J.; van der Brug, M.; Lopez de Munain, A.; Aparicio, S.; Gil, A. M.; Khan, N.; Johnson, J.; Martinez, J. R.; Nicholl, D.; Carrera, I. M.; Pena, A. S.; de Silva, R.; Lees, A.; Marti-Masso, J. F.; Perez-Tur, J.; Wood, N. W.; Singleton, A. B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 2004, 44, 595-600
11. Paisan-Ruiz, C.; Lang, A. E.; Kawarai, T.; Sato, C.; Salehi-Rad, S.; Fisman, G. K.; Al-Khairallah, T.; George-Hyslop, P., St; Singleton, A.; Rogaeva, E. LRRK2 gene in Parkinson disease: mutation analysis and case control association study Neurology 2005, 65, 696-700
12. Paisán-Ruiz, C.; Lewis, P. A.; Singleton, A. B. LRRK2: Cause, risk, and mechanism J. Parkinson's Dis. 2013, 3, 85-103
13. Thévenet, J.; Gobert, R.; van Huijsduijnen, R. H.; Wiessner, C.; Sagot, Y. J. Regulation of LRRK2 expression points to a functional role in human monocyte maturation PLoS One 2011, 6, e21519
14. Sharma, S.; Bandopadhyay, R.; Lashley, T.; Renton, A. E. M.; Kingsbury, A. E.; Kumaran, R.; Kallis, C.; Vilarino-Güell, C.; O'Sullivan, S. S.; Lees, A. J.; Revesz, T.; Wood, N. W.; Holton, J. L. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study Neuropathol. Appl. Neurobiol. 2011, 37, 777-790
15. Mills, R. D.; Mulhern, T. D.; Liu, F.; Culvenor, J. G.; Cheng, H. C. Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2) Hum. Mutat. 2014, 35, 395-412
16. Anand, V. S.; Braithwaite, S. P. LRRK2 in Parkinson's disease: biochemical functions FEBS J. 2009, 276, 6428-6435
17. Drolet, R. E.; Sanders, J. M.; Kern, J. T. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions J. Neurogenet. 2011, 25, 140-151
18. Gilsbach, B. K.; Ho, F. Y.; Vetter, I. R.; van Haastert, P. J. M.; Wittinghofer, A.; Kortholt, A. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 10322-10327
19. Liu, M.; Bender, S. A.; Cuny, G. D.; Sherman, W.; Glicksman, M.; Ray, S. S. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S Biochemistry 2013, 52, 1725-1736
20. Gilsbach, B. K.; Kortholt, A. Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation Front. Mol. Neurosci. 2014, 7, 32
21. Sen, S.; Webber, P. J.; West, A. B. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization J. Biol. Chem. 2009, 284, 36346-36356
22. Ito, G.; Okai, T.; Fujino, G.; Takeda, K.; Ichijo, H.; Katada, T.; Iwatsubo, T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease Biochemistry 2007, 46, 1380-1388
23. 1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations Sci. Transl. Med. 2012, 4, 164ra161
24. West, A. B.; Moore, D. J.; Biskup, S.; Bugayenko, A.; Smith, W. W.; Ross, C. A.; Dawson, V. L.; Dawson, T. M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 16842-16847
25. West, A. B.; Moore, D. J.; Choi, C.; Andrabi, S. A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K. L.; Dawson, V. L.; Dawson, T. M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity Hum. Mol. Genet. 2007, 16, 223-232
26. Jaleel, M.; Nichols, R. J.; Deak, M.; Campbell, D. G.; Gillardon, F.; Knebel, A.; Alessi, D. R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity Biochem. J. 2007, 405, 307-317
27. Silva, R. G.; Geoghegan, K. F.; Qiu, X.; Aulabaugh, A. A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity Anal. Biochem. 2014, 450, 63-69
28. Kachergus, J.; Mata, I. F.; Hulihan, M.; Taylor, J. P.; Lincoln, S.; Aasly, J.; Gibson, J. M.; Ross, O. W.; Lynch, T.; Wiley, J.; Payami, H.; Nutt, J.; Maraganore, D. M.; Czyzewski, K.; Styczynska, M.; Wszolek, Z. K.; Farrer, M. J.; Toft, M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations Am. J. Hum. Genet. 2005, 76, 672-680
29. Smith, W. W.; Pei, Z.; Jiang, H.; Moore, D. J.; Liang, Y.; West, A. B.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18676-18681
30. Gloeckner, C. J.; Kinkl, N.; Schumacher, A.; Braun, R. J.; O'Neill, E.; Meitinger, T.; Kolch, W.; Prokisch, H.; Ueffing, M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity Hum. Mol. Genet. 2006, 15, 223-232
31. Deng, X.; Choi, H. G.; Buhrlage, S. J.; Gray, N. S. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011) Expert Opin. Ther. Pat. 2012, 22, 1415-1426
32. Smith, W. W.; Pei, Z.; Jiang, H.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 2006, 9, 1231-1233
33. Greggio, E.; Jain, S.; Kingsbury, A.; Bandopadhyay, R.; Lewis, P.; Kaganovich, A.; van der Brug, M. P.; Beilina, A.; Blackinton, J.; Thomas, K. J.; Ahmad, R.; Miller, D. W.; Kesavapany, S.; Singleton, A.; Lees, A.; Harvey, R. J.; Harvey, K.; Cookson, M. R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin Neurobiol. Dis. 2006, 2, 329-341
34. MacLeod, D.; Dowman, J.; Hammond, R.; Leete, T.; Inoue, K.; Abeliovich, A. The familial parkinsonism gene LRRK2 regulates neurite process morphology Neuron 2006, 52, 587-593
35. Pchelina, S. N.; Emelyanov, A. K.; Usenko, T. S. Molecular basis of Parkinsons's disease linked to LRRK2 mutations Mol. Biol. 2014, 48, 1-10
36. Zhu, H.; Chen, H.; Cho, W.; Estrada, A. A.; Sweeney, Z. K. From human genetics to drug candidates: An industrial perspective on LRRK2 inhibition as a treatment for Parkinson's disease. In Medicinal Chemistry Approaches to Personalized Medicine; Lackey, K.; Roth, B. D., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2013; pp 227-254.
37. For a recent proposed LRRK2 substrate see the following: Martin, I.; Kim, J. W.; Lee, B. D.; Kang, H. C.; Xu, J. C.; Jia, H.; Stankowski, J.; Kim, M. S.; Zhong, J.; Kumar, M.; Andrabi, S. A.; Xiong, Y.; Dickson, D. W.; Wszolek, Z. K.; Pandey, A.; Dawson, T. M.; Dawson, V. L. Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease Cell 2014, 157, 472-485
38. Russo, I.; Bubacco, L.; Greggio, E. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J. Neuroinflammation 2014, 11, 52
39. Moehle, M. S.; Webber, P. J.; Tse, T.; Sukar, N.; Standaert, D. G.; DeSilva, T. M.; Cowell, R. M.; West, A. B. LRRK2 inhibition attenuates microglial inflammatory responses J. Neurosci. 2012, 32, 1602-1611
40. Reynolds, A.; Doggett, E. A.; Riddle, S. M.; Lebakken, C. S.; Nichols, R. J. LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status Front. Mol. Neurosci. 2014, 7, 54
41. Vancraenenbroeck, R.; De Raeymaecker, J.; Lobbestael, E.; Gao, F.; De Maeyer, M.; Voet, A.; Baekelandt, V.; Taymans, J. M. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2 Front. Mol. Neurosci. 2014, 7, 51
42. Tieu, K. A guide to neurotoxic animal models of Parkinson's disease Cold Spring Harbor Perspect. Med. 2011, 1, a009316
43. Sweeney, Z. K.; Lewcock, J. W. ACS chemical neuroscience spotlight on CEP-1347 ACS Chem. Neurosci. 2011, 2, 3-4
44. Olanow, C. W.; Schapira, A. H.; LeWitt, P. A.; Kieburtz, K.; Sauer, D.; Olivieri, G.; Pohlmann, H.; Hubble, J. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial Lancet Neurol. 2006, 5, 1013-1020
45. Baptista, M. A. S.; Dave, K. D.; Sheth, N. P.; De Silva, S. N.; Carlson, K. M.; Aziz, Y. N.; Fiske, B. K.; Sherer, T. M.; Frasier, M. A. A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's research Dis. Models Mech. 2013, 6, 1316-1324
46. Xu, Q.; Shenoy, S.; Li, C. Mouse models for LRRK2 Parkinson's disease Parkinsonism Relat. Disord. 2012, 18 (Suppl. 1) S186-S189
47. Lee, B. D.; Shin, J. H.; VanKampen, J.; Petrucelli, L.; West, A. B.; Ko, H. S.; Lee, Y. I.; Maguire-Zeiss, K. A.; Bowers, W. J.; Federoff, H. J.; Dawson, V. L.; Dawson, T. M. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease Nat. Med. 2010, 16, 998-1000
48. Yue, Z.; Lachenmayer, M. L. Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications Mov. Disord. 2011, 26, 1386-1397
49. Longo, F.; Russo, I.; Shimshek, D. R.; Greggio, E.; Morari, M. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging Neurobiol. Dis. 2014, 71, 62-73
50. Fuji, R.; Flagella, M.; Baca, M.; Baptista, M. A. S.; Brodbeck, J.; Chan, B. K.; Fiske, B. K.; Honigberg, L.; Jubb, A. M.; Katavolos, P.; Lee, D. W.; Lewin-Koh, S.-C.; Lin, T.; Liu, X.; Liu, S.; Lyssikatos, J. P.; O'Mahony, J.; Reichelt, M.; Roose-Girma, M.; Sheng, Z.; Sherer, T. B.; Smith, A.; Solon, M.; Sweeney, Z. K.; Tarrant, J.; Urkowitz, A.; Warming, S.; Yaylaoglu, M.; Zhang, S.; Zhu, H.; Estrada, A. A.; Watts, R. J. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung Sci. Transl. Med. 2015, 7, 273ra15
51. Tong, Y.; Yamaguchi, H.; Giaime, E.; Boyle, S.; Kopan, R.; Kelleher, R. J.; Shen, J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 9879-9884
52. Tong, Y.; Giaime, E.; Yamaguchi, H.; Ichimura, T.; Liu, Y.; Si, H.; Cai, H.; Bonventre, J. V.; Shen, J. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway Mol. Neurodegener. 2012, 7, 2
53. Herzig, M. C.; Kolly, C.; Persohn, E.; Theil, D.; Schweizer, T.; Hafner, T.; Stemmelen, C.; Troxler, T. J.; Schmid, P.; Danner, S.; Schnell, C. R.; Mueller, M.; Kinzel, B.; Grevot, A.; Bolognani, F.; Stirn, M.; Kuhn, R. R.; Kaupmann, K.; van der Putten, P. H.; Rovelli, G.; Shimshek, D. R. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice Hum. Mol. Genet. 2011, 20, 4209-4223
54. Hinkle, K. M.; Yue, M.; Behrouz, B.; Dächsel, J. C.; Lincoln, S. J.; Bowles, E. E.; Beevers, J. E.; Dugger, B.; Winner, B.; Prots, I.; Kent, C. B.; Nishioka, K.; Lin, W. L.; Dickson, D. W.; Janus, C. J.; Farrer, M. J.; Melrose, H. L. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors Mol. Neurodegener. 2012, 7, 25
55. Baptista, M. A. S.; Dave, K. D.; Frasier, M. A.; Sherer, T. B.; Greeley, M.; Beck, M. J.; Varsho, J. S.; Parker, G. A.; Moore, C.; Churchill, M. J.; Meshul, C. K.; Fiske, B. K. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs PLoS One 2013, 8, e80705
56. Miklavc, P.; Ehinger, K.; Thompson, K. E.; Hobi, N.; Shimshek, D. R.; Frick, M. Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis PLoS One 2014, 9, e84926
57. Kramer, T.; Lo Monte, F.; Göring, S.; Amombo, G. M. O.; Schmidt, B. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models ACS Chem. Neurosci. 2012, 3, 151-160
58. Kavanagh, M. E.; Doddareddy, M. R.; Kassiou, M. The development of CNS-active LRRK2 inhibitors using property-directed optimisation Bioorg. Med. Chem. Lett. 2013, 23, 3690-3696
59. Dzamko, N.; Halliday, G. M. Unlocking the secrets of LRRK2 function with selective kinase inhibitors Future Neurol. 2013, 8, 347-357
60. Schulz, S.; Goring, S.; Schmidt, B.; Hopf, C. LRRK2 kinase inhibitors as new drugs for Parkinson's disease? In Emerging Drugs and Targets for Parkinson's Disease; Martinez, A.; Gil, C., Eds.; RSC Drug Discovery Series No. 34; The Royal Society of Chemistry: London, 2013; pp 266-293.
61. Galatsis, P.; Henderson, J. L.; Kormos, B. L.; Hirst, W. D. Leucine-rich repeat kinase 2 (LRRK2) inhibitors. In Topics in Medicinal Chemistry; Springer: Berlin, 2014; DOI: 10.1007/7355
62. Burdick, D. J. Response to Deng et al.'s LRRK2 patent review Expert Opin. Ther. Pat. 2013, 23, 279-279
63. Kethiri, R. R.; Bakthavatchalam, R. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011-2013) Expert Opin. Ther. Pat. 2013, 24, 745-757
64. Ramsden, N.; Perrin, J.; Ren, Z.; Lee, B. D.; Zinn, N.; Dawson, V. L.; Tam, D.; Bova, M.; Lang, M.; Drewes, G.; Bantscheff, M.; Bard, F.; Dawson, T. M.; Hopf, C. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons ACS Chem. Biol. 2011, 6, 1021-1028
65. Deng, X.; Dzamko, N.; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J.-D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 2011, 7, 203-205
66. Parisiadou, L.; Yu, J.; Sgobio, C.; Xie, C.; Liu, G.; Sun, L.; Gu, X.-L.; Lin, X.; Crowley, N. A.; Lovinger, D. M.; Cai, H. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity Nat. Neurosci. 2014, 17, 367-376
67. Kuss, M.; Adamopoulou, E.; Kahle, P. J. Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages J. Neurochem. 2014, 129, 980-987
68. Elkins, J. M.; Wang, J.; Deng, X.; Pattison, M. J.; Arthur, J. S. C.; Erazo, T.; Gomez, N.; Lizcano, J. M.; Gray, N. S.; Knapp, S. X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor J. Med. Chem. 2013, 56, 4413-4421
69. Weygant, N.; Qu, D.; Berry, W. L.; May, R.; Chandrakesan, P.; Owen, D. B.; Sureban, S. M.; Ali, N.; Janknecht, R.; Houchen, C. W. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1 Mol. Cancer 2014, 13, 103
70. Luerman, G. C.; Nguyen, C.; Samaroo, H.; Loos, P.; Xi, H.; Hurtado-Lorenzo, A.; Needle, E.; Noell, G. S.; Galatsis, P.; Dunlop, J.; Geoghegan, K. F.; Hirst, W. D. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1 J. Neurochem. 2014, 128, 561-576
71. Zhang, J.; Deng, X.; Choi, H. G.; Alessi, D. R.; Gray, N. S. Characterization of TAE684 as a potent LRRK2 kinase inhibitor Bioorg. Med. Chem. Lett. 2012, 22, 1864-1869
72. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270-275
73. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051
74. Galatsis, P.; Henderson, J. L.; Kormos, B. L.; Han, S.; Kurumbail, R. G.; Wager, T. T.; Verhoest, P. R.; Noell, G. S.; Chen, Y.; Needle, E.; Berger, Z.; Steyn, S. J.; Houle, C.; Hirst, W. D. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold Bioorg. Med. Chem. Lett. 2014, 24, 4132-4140
75. Franzini, M.; Ye, X. M.; Adler, M.; Aubele, D. L.; Garofalo, A. W.; Gauby, S.; Goldbach, E.; Probst, G. D.; Quinn, K. P.; Santiago, P.; Sham, H. L.; Tam, D.; Truong, A.; Ren, Z. Triazolopyridazine LRRK2 kinase inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 1967-1973
76. Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure J. Med. Chem. 2015, 58, 2584-2608
77. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond the rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449
78. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of a compound J. Med. Chem. 2012, 55, 4877-4895
79. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583
80. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of succesful central nervous system drugs NeuroRx 2005, 2, 541-553
81. Ghose, A. K.; Herbertz, T.; Hudkins, R. L.; Dorsey, B. D.; Mallamo, J. P. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery ACS Chem. Neurosci. 2012, 18, 50-68
82. Liu, X.; Wright, M.; Hop, C. E. C. A. Rational use of plasma protein and tissue binding data in drug design J. Med. Chem. 2014, 57, 8238-8248
83. Chen, H.; Chan, B. K.; Drummond, J.; Estrada, A. A.; Gunzner-Toste, J.; Liu, X.; Liu, Y.; Moffat, J. G.; Shore, D.; Sweeney, Z. K.; Tran, T.; Wang, S.; Zhao, G.; Zhu, H.; Burdick, D. J. Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling J. Med. Chem. 2012, 55, 5536-5545
84. Choi, H. G.; Zhang, J.; Deng, X.; Hatcher, J. M.; Patricelli, M. P.; Zhao, Z.; Alessi, D. R.; Gray, N. S. Brain penetrant LRRK2 inhibitor ACS Med. Chem. Lett. 2012, 3, 658-662
85. Estrada, A. A.; Liu, X.; Baker-Glenn, C.; Beresford, A.; Burdick, D. J.; Chambers, M.; Chan, B. K.; Chen, H.; Ding, X.; DiPasquale, A. G.; Dominguez, S. L.; Dotson, J.; Drummond, J.; Flagella, M.; Flynn, S.; Fuji, R.; Gill, A.; Gunzner-Toste, J.; Harris, S. F.; Heffron, T. P.; Kleinheinz, T.; Lee, D. W.; Le Pichon, C. E.; Lyssikatos, J. P.; Medhurst, A. D.; Moffat, J. G.; Mukund, S.; Nash, K.; Scearce-Levie, K.; Sheng, Z.; Shore, D. G.; Tran, T.; Trivedi, N.; Wang, S.; Zhang, S.; Zhang, X.; Zhao, G.; Zhu, H.; Sweeney, Z. K. Discovery of highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors J. Med. Chem. 2012, 55, 9416-9433
86. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
87. Estrada, A. A.; Chan, B. K.; Baker-Glenn, C.; Beresford, A.; Burdick, D. J.; Chambers, M.; Chen, H.; Dominguez, S. L.; Dotson, J.; Drummond, J.; Flagella, M.; Fuji, R.; Gill, A.; Halladay, J.; Harris, S. F.; Heffron, T. P.; Kleinheinz, T.; Lee, D. W.; Le Pichon, C. E.; Liu, X.; Lyssikatos, J. P.; Medhurst, A. D.; Moffat, J. G.; Nash, K.; Scearce-Levie, K.; Sheng, Z.; Shore, D. G.; Wong, S.; Zhang, S.; Zhang, X.; Zhu, H.; Sweeney, Z. K. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors J. Med. Chem. 2014, 57, 921-936
88. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfronga, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration Drug Metab. Dispos. 2006, 34, 1443-1447
89. Lin, J. H. CSF as a surrogate for assessing CNS exposure: An industrial perspective Curr. Drug Metab. 2008, 9, 46-59
90. Reith, A. D.; Bamborough, P.; Jandu, K.; Andreotti, D.; Mensah, L.; Dossang, P.; Choi, H. G.; Deng, X.; Zhang, J.; Alessi, D. R.; Gray, N. S. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substituent-N-arylbenzamide LRRK2 kinase inhibitor Bioorg. Med. Chem. Lett. 2012, 22, 5625-5629
91. Cirnaru, M. D.; Marte, A.; Belluzzi, E.; Russo, I.; Gabrielli, M.; Longo, F.; Arcuri, L.; Murru, L.; Bubacco, L.; Matteoli, M.; Fedele, E.; Sala, C.; Passafaro, M.; Morari, M.; Greggio, E.; Onofri, F.; Piccoli, G. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex Front. Mol. Neurosci. 2014, 7, 49
92. Nichols, P. L.; Eatherton, A. J.; Bamborough, P.; Jandu, K. S.; Philps, O. J.; Andreotti, D. Novel compounds. WO 2011/038572 A1, 2011.
93. Afsari, F.; Christensen, K. V.; Smith, G. P.; Hentzer, M.; Nippe, O. M.; Elliott, C. J. H.; Wade, A. R. Abnormal visual gain control in a Parkinson's disease model Hum. Mol. Genet. 2014, 23, 4465-4478
94. Garofalo, A. W.; Adler, M.; Aubele, D. L.; Brigham, E. F.; Chian, D.; Franzini, M.; Goldbach, E.; Kwong, G. T.; Motter, R.; Probst, G. D.; Quinn, K. P.; Ruslim, L.; Sham, H. L.; Tam, D.; Tanaka, P.; Truong, A. P.; Ye, X. M.; Ren, Z. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 1974-1977
95. Troxler, T.; Greenidge, P.; Zimmermann, K.; Desrayaud, S.; Druckes, P.; Schweizer, T.; Stauffer, D.; Rovelli, G.; Shimshek, D. R. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2 Bioorg. Med. Chem. Lett. 2013, 23, 4085-4090
96. Nichols, R. J.; Dzamko, N.; Hutti, J. E.; Cantley, L. C.; Deak, M.; Moran, J.; Bamborough, P.; Reith, A. D.; Alessi, D. R. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease Biochem. J. 2009, 424, 47-60
97. Dzamko, N.; Deak, M.; Hentati, F.; Reith, A. D.; Prescott, A. R.; Alessi, D. R.; Nichols, R. J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization Biochem. J. 2010, 430, 405-413
98. Chan, B. K.; Chen, H.; Estrada, A.; Shore, D.; Sweeney, Z.; McIver, E. G. Compounds and their administration for treating a neurodegerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK2. US 8569281 B2, 2013.
99. Chan, B.; Estrada, A.; Shore, D.; Sweeney, Z. Pyrazolopyridines for treatment of Parkinson's disease. WO 2013/139882 A1, 2013.
100. Vankayalapati, H.; Appalaneni, R. P.; Reddy, Y. V. K. Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-B]pyridine and pyrazolo[3,4-B]pyridine derivatives as protein kinase inhibitors. WO 2012/135631 A1, 2012.
101. Almstetter, M.; Thormann, M.; Treml, A.; Koestler, R.; Yehia, N. Heterocyclic compounds as kinase inhibitors. WO 2012/143143 A1, 2012.
102. Almstetter, M.; Thormann, M.; Treml, A.; Traube, N. Pyrazolo[4,3-D]pyrimidines useful as kinase inhibitors. WO 2012/143144 A1, 2012.
103. Chan, B.; Estrada, A.; Sweeney, Z.; McIver, E. G. Pyrazolopyridines as inhibitors of the kinase LRRK2. WO 2011/141756 A1, 2011.
104. McIver, E. G.; Smiljanic, E.; Harding, D. J.; Hough, J. Compounds. WO 2010/106333 A1, 2010.
105. Henderson, J. L.; Kormos, B. L.; Hayward, M. M.; Coffman, K. J.; Jasti, J.; Kurumbail, R. G.; Wager, T. T.; Verhoest, P. R.; Noell, G. S.; Chen, Y.; Needle, E.; Berger, Z.; Steyn, S. J.; Houle, C.; Hirst, W. D.; Galatsis, P. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor J. Med. Chem. 2015, 58, 419-432
106. Galatsis, P.; Hayward, M. M.; Kormos, B. L.; Wager, T. T.; Zhang, L.; Stepan, A. F.; Henderson, J. L.; Kurumbail, R. G.; Verhoest, P. R. Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors. WO 2014/001973 A1, 2014.
107. Patricelli, M. P.; Nomanbhoy, T. K.; Wu, J.; Brown, H.; Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J.-D.; Gray, N. S.; Kozarich, J. W. In situ kinase profiling reveals functionally relevant properties of native kinases Chem. Biol. 2011, 18, 699-710
108. Deng, J.; Lewis, P. A.; Greggio, E.; Sluch, E.; Beilina, A.; Cookson, M. R. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1499-1504
109. Li, T.; Yang, D.; Zhong, S.; Thomas, J. M.; Xue, F.; Liu, J.; Kong, L.; Voulalas, P.; Hassan, H. E.; Park, J.-S.; MacKerell, A. D., Jr; Smith, W. W. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models Hum. Mol. Genet. 2014, 23, 6212-6222
110. Gardet, A.; Benita, Y.; Li, C.; Sands, B. E.; Ballester, I.; Stevens, C.; Korzenik, J. R.; Rioux, J. D.; Daly, M. J.; Xavier, R. J.; Podolsky, D. K. LRRK2 is involved in the IFN-gamma response and host response to pathogens J. Immunol. 2010, 185, 5577-5585